MoonLake Immunotherapeutics Future Growth
Future criteria checks 0/6
MoonLake Immunotherapeutics's earnings are forecast to decline at 4.2% per annum while its annual revenue is expected to grow at 84.3% per year. EPS is expected to decline by 0.4% per annum. Return on equity is forecast to be -62.8% in 3 years.
Key information
-4.2%
Earnings growth rate
-0.4%
EPS growth rate
| Biotechs earnings growth | 30.0% |
| Revenue growth rate | 84.3% |
| Future return on equity | -62.8% |
| Analyst coverage | Good |
| Last updated | 12 Aug 2024 |
Recent future growth updates
Recent updates
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
Aug 27
MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
Jul 18Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
May 14MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3
Feb 26We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn
Jan 29Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
Oct 16Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics
Jul 26Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -222 | -246 | -220 | 6 |
| 12/31/2025 | N/A | -143 | -147 | -160 | 10 |
| 12/31/2024 | N/A | -78 | -106 | -106 | 10 |
| 6/30/2024 | N/A | -55 | -65 | -64 | N/A |
| 3/31/2024 | N/A | -41 | -49 | -49 | N/A |
| 12/31/2023 | N/A | -36 | -43 | -43 | N/A |
| 9/30/2023 | N/A | -46 | -42 | -42 | N/A |
| 6/30/2023 | N/A | -46 | -42 | -42 | N/A |
| 3/31/2023 | N/A | -48 | -51 | -51 | N/A |
| 12/31/2022 | N/A | -50 | -56 | -56 | N/A |
| 9/30/2022 | N/A | -58 | -59 | -59 | N/A |
| 6/30/2022 | N/A | -54 | -52 | -51 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MLTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MLTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MLTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MLTX is forecast to have no revenue next year.
High Growth Revenue: MLTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MLTX is forecast to be unprofitable in 3 years.